A detailed history of Oppenheimer Asset Management Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 13,758 shares of NBIX stock, worth $1.86 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,758
Previous 15,146 9.16%
Holding current value
$1.86 Million
Previous $2.09 Million 24.08%
% of portfolio
0.02%
Previous 0.03%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$114.58 - $153.15 $159,037 - $212,572
-1,388 Reduced 9.16%
13,758 $1.58 Million
Q2 2024

Aug 08, 2024

BUY
$130.86 - $143.19 $225,733 - $247,002
1,725 Added 12.85%
15,146 $2.09 Million
Q1 2024

May 06, 2024

SELL
$130.4 - $143.74 $268,102 - $295,529
-2,056 Reduced 13.28%
13,421 $1.85 Million
Q4 2023

Feb 13, 2024

SELL
$106.07 - $132.76 $47,943 - $60,007
-452 Reduced 2.84%
15,477 $2.04 Million
Q3 2023

Nov 07, 2023

BUY
$94.02 - $117.1 $163,218 - $203,285
1,736 Added 12.23%
15,929 $1.79 Million
Q2 2023

Aug 02, 2023

SELL
$89.53 - $104.87 $1.08 Million - $1.26 Million
-12,027 Reduced 45.87%
14,193 $1.34 Million
Q1 2023

May 10, 2023

SELL
$94.11 - $123.02 $18,445 - $24,111
-196 Reduced 0.74%
26,220 $2.65 Million
Q4 2022

Feb 06, 2023

SELL
$106.72 - $127.06 $409,057 - $487,020
-3,833 Reduced 12.67%
26,416 $3.16 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $316,951 - $371,297
-3,444 Reduced 10.22%
30,249 $3.21 Million
Q2 2022

Aug 08, 2022

SELL
$75.79 - $100.07 $69,726 - $92,064
-920 Reduced 2.66%
33,693 $3.29 Million
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $592,568 - $775,450
8,179 Added 30.94%
34,613 $3.25 Million
Q4 2021

Feb 02, 2022

SELL
$79.65 - $106.22 $188,133 - $250,891
-2,362 Reduced 8.2%
26,434 $2.25 Million
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $30,507 - $35,056
354 Added 1.24%
28,796 $2.76 Million
Q2 2021

Aug 03, 2021

BUY
$89.43 - $102.27 $60,275 - $68,929
674 Added 2.43%
28,442 $2.77 Million
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $221,727 - $302,320
2,532 Added 10.03%
27,768 $2.7 Million
Q4 2020

Feb 11, 2021

SELL
$86.91 - $108.33 $55,535 - $69,222
-639 Reduced 2.47%
25,236 $2.42 Million
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $1.55 Million - $2.18 Million
16,149 Added 166.04%
25,875 $2.49 Million
Q2 2020

Aug 11, 2020

BUY
$85.09 - $130.36 $66,795 - $102,332
785 Added 8.78%
9,726 $1.19 Million
Q1 2020

May 08, 2020

BUY
$75.11 - $113.76 $103,877 - $157,330
1,383 Added 18.3%
8,941 $774,000
Q4 2019

Feb 07, 2020

BUY
$86.8 - $118.57 $7,117 - $9,722
82 Added 1.1%
7,558 $812,000
Q3 2019

Oct 31, 2019

BUY
$83.82 - $101.5 $17,099 - $20,706
204 Added 2.81%
7,476 $674,000
Q2 2019

Aug 09, 2019

SELL
$72.24 - $91.27 $14,664 - $18,527
-203 Reduced 2.72%
7,272 $614,000
Q1 2019

Apr 24, 2019

BUY
$69.31 - $91.53 $48,517 - $64,071
700 Added 10.33%
7,475 $659,000
Q4 2018

Jan 30, 2019

BUY
$68.32 - $124.36 $462,867 - $842,539
6,775 New
6,775 $484,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.